


# Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma

January 15 2024



B) Transaxial CT and PET slices at the lung metastasis level in the left lung on the left. Maximum intensity projection (MIP)-PET whole body images on the right. The upper row shows images in April 2018 when there was no evidence of metabolic active disease. The lower row images in January 2020 demonstrate a relapse in the left lung, which is seen transaxial images and as a tiny spot in the MIP-image. Credit: 2023 Gouda et al.

A new case report was published in *Oncoscience* on September 20, 2023, titled, "[Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma.](#)"

In this case report researchers discuss the case of a patient with a EWSR1-NFATC2 fusion positive bone sarcoma who had exceptional tumor control through using pazopanib and surgery for an overall duration exceeding five years. The report also reviews the literature on EWSR1-NFATC2 translocation-associated sarcomas and use of pazopanib in bone sarcomas.

The researchers include Mohamed A. Gouda, Maria A. Zarzour, Ara A. Vaporciyan, Kalevi Kairemo, Hubert H. Chuang, and Vivek Subbiah from The University of Texas MD Anderson Cancer Center and Sarah Cannon Research Institute

Pazopanib, a multi-kinase VEGF inhibitor, is currently FDA approved for advanced renal cell carcinoma and advanced soft tissue sarcoma; but limited evidence exists on its efficacy in bone sarcomas.

"In brief, this case, in accordance with previously reported evidence, provides proof of activity of pazopanib in EWSR1-NFATC2 positive [sarcoma](#). The report shows that pazopanib when administered in an adjuvant capacity demonstrated its effectiveness in preventing or delaying the progression of additional metastasis. Nevertheless, due to the adjuvant nature of the treatment, it remains uncertain whether this approach would have resulted in tumor shrinkage. Further preclinical studies and [clinical studies](#) using pazopanib in EWSR1-NFATC2 sarcomas are warranted," the researchers conclude.

**More information:** Mohamed A. Gouda et al, Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma, *Oncoscience* (2023). [DOI: 10.18632/oncoscience.587](https://doi.org/10.18632/oncoscience.587)

Provided by Impact Journals LLC

Citation: Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma (2024, January 15) retrieved 9 May 2024 from

<https://medicalxpress.com/news/2024-01-pazopanib-ewsr1-nfatc2-translocation-bone.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--